Media stories about Core Laboratories (NYSE:CLB) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Core Laboratories earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news stories about the oil and gas company an impact score of 45.5805833165442 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s analysis:

Shares of Core Laboratories (CLB) traded down $0.96 during trading on Friday, reaching $106.88. The company had a trading volume of 315,386 shares, compared to its average volume of 649,281. Core Laboratories has a fifty-two week low of $86.55 and a fifty-two week high of $125.83. The company has a market cap of $4,680.00, a PE ratio of 61.78 and a beta of 1.55. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 1.53.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.04. Core Laboratories had a return on equity of 52.89% and a net margin of 12.06%. The business had revenue of $166.20 million for the quarter, compared to analysts’ expectations of $160.94 million. During the same period in the previous year, the business posted $0.38 EPS. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. research analysts predict that Core Laboratories will post 1.99 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada set a $110.00 price target on shares of Core Laboratories and gave the stock a “buy” rating in a report on Thursday. Loop Capital set a $115.00 price target on shares of Core Laboratories and gave the stock a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded shares of Core Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. UBS Group cut their price target on shares of Core Laboratories from $110.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, October 25th. Finally, ABN Amro raised shares of Core Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, October 25th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $110.20.

COPYRIGHT VIOLATION NOTICE: “Core Laboratories (CLB) Earning Somewhat Favorable News Coverage, Study Finds” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Insider Buying and Selling by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with's FREE daily email newsletter.